vs
Side-by-side financial comparison of BlackSky Technology Inc. (BKSY) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
BlackSky Technology Inc. is the larger business by last-quarter revenue ($35.2M vs $18.7M, roughly 1.9× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -2.5%, a 1.6% gap on every dollar of revenue. On growth, BlackSky Technology Inc. posted the faster year-over-year revenue change (15.9% vs -25.7%). Over the past eight quarters, BlackSky Technology Inc.'s revenue compounded faster (20.5% CAGR vs -15.9%).
BlackSky Technology Inc. is a leading geospatial intelligence provider operating a constellation of high-revisit small Earth observation satellites. It delivers real-time satellite imagery, advanced data analytics, and dynamic monitoring solutions to government, defense, critical infrastructure, and commercial clients globally to support data-driven operational decision-making.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BKSY vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $18.7M |
| Net Profit | $-868.0K | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -11.8% | -6.9% |
| Net Margin | -2.5% | -0.8% |
| Revenue YoY | 15.9% | -25.7% |
| Net Profit YoY | 95.5% | 97.6% |
| EPS (diluted) | $0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | — | ||
| Q3 25 | $19.6M | — | ||
| Q2 25 | $22.2M | $18.7M | ||
| Q1 25 | $29.5M | $50.9M | ||
| Q4 24 | $30.4M | $38.1M | ||
| Q3 24 | $22.5M | $33.4M | ||
| Q2 24 | $24.9M | $25.1M | ||
| Q1 24 | $24.2M | $41.5M |
| Q4 25 | $-868.0K | — | ||
| Q3 25 | $-15.3M | — | ||
| Q2 25 | $-41.2M | $-154.0K | ||
| Q1 25 | $-12.8M | $23.5M | ||
| Q4 24 | $-19.4M | $18.9M | ||
| Q3 24 | $-12.6M | $5.7M | ||
| Q2 24 | $-9.4M | $-6.5M | ||
| Q1 24 | $-15.8M | $13.8M |
| Q4 25 | -11.8% | — | ||
| Q3 25 | -85.8% | — | ||
| Q2 25 | -62.8% | -6.9% | ||
| Q1 25 | -40.5% | 44.4% | ||
| Q4 24 | -20.0% | 46.4% | ||
| Q3 24 | -58.7% | 12.3% | ||
| Q2 24 | -47.0% | -33.7% | ||
| Q1 24 | -54.7% | 28.1% |
| Q4 25 | -2.5% | — | ||
| Q3 25 | -78.2% | — | ||
| Q2 25 | -185.8% | -0.8% | ||
| Q1 25 | -43.4% | 46.2% | ||
| Q4 24 | -63.9% | 49.6% | ||
| Q3 24 | -55.8% | 17.2% | ||
| Q2 24 | -37.7% | -26.0% | ||
| Q1 24 | -65.2% | 33.3% |
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.44 | — | ||
| Q2 25 | $-1.27 | — | ||
| Q1 25 | $-0.42 | — | ||
| Q4 24 | $-0.61 | — | ||
| Q3 24 | $-0.66 | — | ||
| Q2 24 | $-0.52 | — | ||
| Q1 24 | $-0.88 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $124.5M | $49.0M |
| Total DebtLower is stronger | $201.1M | — |
| Stockholders' EquityBook value | $94.9M | $119.9M |
| Total Assets | $386.2M | $175.1M |
| Debt / EquityLower = less leverage | 2.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.5M | — | ||
| Q3 25 | $146.5M | — | ||
| Q2 25 | $93.8M | $49.0M | ||
| Q1 25 | $75.8M | $47.6M | ||
| Q4 24 | $52.5M | $38.1M | ||
| Q3 24 | $63.2M | $40.6M | ||
| Q2 24 | $41.2M | $43.2M | ||
| Q1 24 | $35.4M | $36.2M |
| Q4 25 | $201.1M | — | ||
| Q3 25 | $195.1M | — | ||
| Q2 25 | $122.5M | — | ||
| Q1 25 | $115.3M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $98.8M | — | ||
| Q2 24 | $108.6M | — | ||
| Q1 24 | $85.0M | — |
| Q4 25 | $94.9M | — | ||
| Q3 25 | $91.1M | — | ||
| Q2 25 | $86.6M | $119.9M | ||
| Q1 25 | $88.8M | $25.0M | ||
| Q4 24 | $94.0M | $-456.0K | ||
| Q3 24 | $110.3M | $-23.5M | ||
| Q2 24 | $76.5M | $-31.2M | ||
| Q1 24 | $81.7M | $-31.7M |
| Q4 25 | $386.2M | — | ||
| Q3 25 | $380.9M | — | ||
| Q2 25 | $310.8M | $175.1M | ||
| Q1 25 | $284.9M | $98.5M | ||
| Q4 24 | $254.1M | $120.5M | ||
| Q3 24 | $245.5M | $139.0M | ||
| Q2 24 | $224.3M | $159.2M | ||
| Q1 24 | $210.1M | $184.7M |
| Q4 25 | 2.12× | — | ||
| Q3 25 | 2.14× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | 1.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.3M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.3M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-7.3M | $-15.8M | ||
| Q1 25 | $27.2M | $-21.0M | ||
| Q4 24 | $-1.8M | $-19.9M | ||
| Q3 24 | $1.0M | $-20.7M | ||
| Q2 24 | $-1.8M | $-19.5M | ||
| Q1 24 | $-3.8M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BKSY
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
